PC
MRTX

Pier Capital’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Pier Capital’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-61,065
Closed -$10.8M – 130
2021
Q3 		$10.8M Sell
61,065
-2,186
-3% -$352K 1.12% 44
2021
Q2 		$10.2M Buy
63,251
+19,033
+43% +$3.06M 1.02% 60
2021
Q1 		$7.58M Buy
44,218
+17,128
+63% +$3.39M 0.72% 79
2020
Q4 		$5.95M Buy
27,090
+845
+3% +$183K 0.63% 87
2020
Q3 		$4.36M Sell
26,245
-43,521
-62% -$5.96M 0.64% 88
2020
Q2 		$7.96M Buy
69,766
+7,494
+12% +$727K 1.27% 19
2020
Q1 		$4.79M Buy
+62,272
New +$5.58M 1.06% 48

Other funds holding MRTX

Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
RTW Investments
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Pier Capital's MRTX Position: Q4 2021 in Review

Pier Capital sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q4 2021, closing a stake of 61,065 shares — an estimated $10.8M sold.

Pier Capital first reported a position in MRTX in Q1 2020 and held it in 7 quarters. The position peaked at $10.8M in Q3 2021. 260 funds tracked by Wall St. Rank hold MRTX as of Q4 2021.

  • Pier Capital reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Pier Capital sold 61,065 Mirati Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $10.8M.
  • Pier Capital first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2020 and held it in 7 quarters.
  • Pier Capital's Mirati Therapeutics, Inc. Common Stock position peaked at $10.8M in Q3 2021.
  • 260 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Pier Capital's 13F filing for Q4 2021, filed 10 Feb 2022.